What was the biggest price drop for MRNA?

The deepest fall in our weekly price history since December 2018 was 94.77%, from a high in the week of September 6, 2021 to a low in the week of September 8, 2025. The price has not yet returned to that high.

Which month has historically been best for MRNA?

Since 2019, November has had the highest average return for MRNA (+16.59%, up in 4 of 7 years) and October the lowest (-1.70%, up in 3 of 7 years). Past seasonal patterns do not predict future returns.

stock · yahoo

MRNA

$218.01

▼ 18.49 (-7.82%)

Last close · Oct 16

Below: live stock price for MRNA (MRNA), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

MRNA (MRNA) is a Healthcare company based in United States. Operating in Biotechnology, it employs about 4,700 people. Over the past year MRNA traded between 22.28 and 242.29 USD.

Day

-7.82%

-18.49

Week

-3.11%

-6.99

Month

+41.53%

+63.97

Year

+738.18%

+192.00

Prev close: $236.50
Volume (24h): —
Market cap: —
Currency: USD

Score

56/ 100 · Mixed

Coverage: 7/7

Value50
Quality0
Momentum100
Growth32
Risk82
Dividend50
Liquidity76

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 83%Pace +2.74% per bar

+5 bars+20 bars+60 bars+120 bars

+5 bars: 242.3476
+20 bars: 280.4505
+60 bars: 296.7495
+120 bars: 297.3648

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.2122 USD.

Interpretation

Composite signals look mixed. Strength: momentum with weakness: quality. Price sits near the upper third of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

Value
50/100
Value looks mixed — driven by P/E (-49.13).
P/E:-49.13P/B:12.87
Quality
0/100
Quality looks fragile — driven by Profit margin (-141.43%).
ROE:-39.00%ROA:-13.26%Profit margin:-141.43%Gross margin:-66.02%
Momentum
100/100
Momentum looks strong — driven by 52w change (700.33%).
52w change:700.33%
Growth
32/100
Growth looks weak — driven by Revenue growth (2.10%).
Revenue growth:2.10%
Risk
82/100
Risk looks strong — driven by Debt / equity (19.04).
Beta:1.1Debt / equity:19.04Short interest:9.44%
Dividend
50/100
Dividend looks mixed — driven by Dividend yield (0.00%).
Dividend yield:0.00%Payout ratio:0.00%
Liquidity
76/100
Liquidity looks strong — driven by Current ratio (2.3).
Current ratio:2.3Quick ratio:2.07

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 251 days.

Position in range89%

22.28 low242.29 high

Where the price sits between the window low and high.

Volatility (annualised): 128.9%
Max drawdown: -34.2%
Below period high: -10.0%
Best day: +176.97%
Worst day: -23.55%
Up days: 53%
Current streak: 1 down
Typical day swing: 6.7%
Volume vs average: +291%

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above

293.8694 USD+34.80%

Fib +27.2% extension

Next level below

197.5373 USD-9.39%

Fib 23.6% retracement

Levels derived from: 242.29 high → 52.66 low · 60 bars

Resistance
Fib +161.8% extension
not reached
549.1113 USD
+151.87% from current
Resistance
Fib +100% extension
not reached
431.92 USD
+98.12% from current
Resistance
Fib +61.8% extension
not reached
359.4813 USD
+64.89% from current
Resistance
Fib +27.2% extension
not reached
293.8694 USD
+34.80% from current
Current
218.01 USD
Support
Fib 23.6% retracementNearest
tested 9×
197.5373 USD
-9.39% from current
Support
Fib 38.2% retracement
tested 3×
169.8513 USD
-22.09% from current
Support
Fib 50% midpoint
tested 14×
147.475 USD
-32.35% from current
Support
Fib 61.8% retracement
tested 1×
125.0987 USD
-42.62% from current
Support
Fib 78.6% retracement
not reached
93.2408 USD
-57.23% from current
Support
Fib −27.2% extension
not reached
1.0806 USD
-99.50% from current
Support
Fib −61.8% extension
not reached
-64.5313 USD
-129.60% from current
Support
Fib −100% extension
not reached
-136.97 USD
-162.83% from current

How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high: $242.29
52w low: $22.28
52w change: 700.33%
Day high: $237.96
Day low: $208.92
Forward P/E: -49.13
Price / Book: 12.87
Beta (5Y): 1.1
Enterprise value: 83.19B
EV / Revenue: 37.34
EV / EBITDA: -37.9
EPS (TTM): -$7.98
Forward EPS: -$4.44
Dividend yield: 0.00%
Payout ratio: 0.00%
Revenue (TTM): 2.23B
EBITDA: -2.2B
Free cash flow: 299.25M
Total cash: 5.14B
Total debt: 1.29B
Debt / Equity: 19.04
Current ratio: 2.3
Quick ratio: 2.07
Profit margin: -141.43%
Gross margin: -66.02%
Return on assets: -13.26%
Return on equity: -39.00%
Shares outstanding: 399.24M
Float: 371.98M

Sector: HealthcareIndustry: BiotechnologyHQ: United StatesEmployees: 4.7Kwww.modernatx.com

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Analyst & Risk

Consensus

Hold

Mean rating2.87 / 5

Analysts18

Next earnings2026-11-06

Strong buy 1Buy 4Hold 14Sell 2Strong sell 2

Analyst price target

$123.61

Mean target · 18 analysts

-43.3%

upside

Low $45.00Now $218.01High $200.00

Beta (vs S&P 500): 1.1; slightly more volatile
52-week change: 700.33%
Short % of float: 9.44%
Short ratio (days): 2
Debt / Equity: 19.04; very high leverage
Current ratio: 2.3
Quick ratio: 2.07
ROE: -39.00%
ROA: -13.26%
EV / Revenue: 37.34
EV / EBITDA: -37.9
Revenue growth: 2.10%
EBITDA: -2.2B
Free cash flow: 299.25M
Total cash: 5.14B
Total debt: 1.29B
Insider holdings: 7.34%
Institutional: 80.56%

Recent rating changes

2026-10-15Goldman SachsNeutral → Neutralmain
2026-10-07Morgan StanleyEqual-Weight → Equal-Weightmain
2026-09-30CitigroupNeutral → Selldown
2026-09-03Rothschild & CoNeutral → Selldown
2026-08-28Argus ResearchHold → Buyup
2026-08-25Wolfe ResearchUnderperform → Peer Performup
2026-08-24BarclaysEqual-Weight → Equal-Weightmain
2026-08-21JP MorganUnderweight → Underweightmain

Financial documents

MRNA performance

Change from the closing price at the start of each period to the latest price.

Period	Start price	Change	Per year
1 week$225.00	$225.00	-3.11%
1 month$145.62	$145.62	+49.71%
3 months$63.15	$63.15	+245.2%
6 months$54.68	$54.68	+298.7%
Year to date$29.49	$29.49	+639.3%
1 year$26.01	$26.01	+738.2%
3 years$98.30	$98.30	+121.8%	+30.29%
5 years$324.21	$324.21	-32.76%	-7.63%
Since Dec 2018$18.60	$18.60	+1,072%	+36.78%

Periods up to a year use daily closes, longer ones weekly closes. “Per year” is the compound annual growth rate.

Price change only; dividends are not included.

MRNA all-time high and low

All-time high

$497.49

week of Aug 9, 2021

56.18% below the high

All-time low

$11.54

week of Aug 5, 2019

1,789% above the low

52-week range

89%

Low

$22.28

Nov 21, 2025

High

$242.29

Oct 15, 2026

The latest price sits at 89% of this range.

Highs and lows include intraday prices.

MRNA risk metrics

Past year of daily closes unless stated otherwise.

Volatility (1 year, annualised): 128.9%; How large price swings have been: the standard deviation of daily returns, scaled up to a year.
Max drawdown (1 year): -34.16%; Jul 6, 2026 → Aug 6, 2026 · Recovered on Aug 19, 2026.; The deepest fall from a previous high to a later low over the past year.
Max drawdown (since Dec 2018): -94.77%; Sep 2021 → Sep 2025 · Not yet recovered.; The same measure across the whole weekly price history.
Sharpe ratio (risk-free rate 0): 1.66; Average daily return divided by its volatility, annualised: higher means more return for each unit of risk over the past year.
Beta vs S&P 500 (1 year): 2.15; On average, MRNA moved 2.15% for each 1% move in the S&P 500 on the same day.

MRNA drawdown from peak

How far the price stood below its previous high, based on weekly closes since Dec 2018.

MRNA seasonality

Monthly returns by year, from month-end closes: daily data for the past year, weekly closes before that.

MRNA seasonality
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	+49%	+22%	-5.2%	-9.6%	+2.7%	+48%	-22%	+156%	+37%	+13%*			+639%*
2025	-1.8%	-21%	+0.5%

MRNA price history

Yearly open, high, low and close, newest first.

MRNA price history
Year	Open	High	Low	Close	Change
2026YTD	$29.83	$242.29	$29.81	$218.01	+639.3%
2025	$39.74	$48.92	$22.28	$29.49	-26.51%
2024	$99.88	$170.47	$35.80	$40.13	-59.65%
2023	$180.85	$207.51	$62.55	$99.45	-44.63%
2022	$247.12	$249.42	$115.03	$179.62	-29.28%

Frequently asked questions about MRNA

What is the price of MRNA today?

As of October 16, 2026, the price of MRNA is $218.01, down 7.82% from the previous close.

What is the all-time high of MRNA?

The all-time high of MRNA is $497.49, reached in the week of August 9, 2021. At $218.01, the latest price is 56.18% below that peak.

How much has MRNA gained this year?

MRNA is up 639.3% so far in 2026: it closed 2025 at $29.49 and is at $218.01 now.

How volatile is MRNA?

Over the past year, MRNA had an annualised volatility of 128.9%, based on daily closes. Its deepest fall from a high in that time was 34.16%, from July 6, 2026 to August 6, 2026. Its beta against the S&P 500 was 2.15.

Calculated from historical closing prices — daily for the past year, weekly before that — and refreshed as new prices arrive. Past performance does not predict future returns. Not investment advice.


Average	+13%	+1.9%	+3.5%	+8.1%	+6.0%	+2.6%	+8.5%	+12%	-0.6%	-1.7%	+17%	-1.7%	+65%
Years up	75%	38%	63%	50%	63%	50%	63%	38%	50%	43%	57%	43%	43%

Year	Open	High	Low	Close	Change
2021	$107.23	$497.49	$103.26	$253.98	+143.1%
2020	$19.54	$178.50	$17.68	$104.47	+435.2%
2019	$14.24	$29.79	$11.54	$19.52	+37.95%
2018from December	$22.00	$22.75	$13.03	$14.15	—

Month	Close	Change
September 2026	$192.57	+37.22%
August 2026	$140.34	+156.0%
July 2026	$54.82	-21.72%
June 2026	$70.03	+48.40%
May 2026	$47.19	+2.72%
April 2026	$45.94	-9.57%

Month	Close	Change
March 2026	$50.80	-5.17%
February 2026	$53.57	+21.56%
January 2026	$44.07	+49.44%
December 2025	$29.49	+13.51%
November 2025	$25.98	-4.34%
October 2025	$27.16	+10.90%

MRNA

Financials

Analyst & Risk

Recent rating changes

Financial documents

MRNA performance

MRNA all-time high and low

52-week range

MRNA risk metrics

MRNA drawdown from peak

MRNA seasonality

MRNA price history

Frequently asked questions about MRNA

What is the price of MRNA today?

What is the all-time high of MRNA?

How much has MRNA gained this year?

How volatile is MRNA?

Recent news

Learn the terms

Live discussion

MRNA performance

MRNA all-time high and low

52-week range

MRNA risk metrics

MRNA drawdown from peak

MRNA seasonality

MRNA price history

Frequently asked questions about MRNA

What is the price of MRNA today?

What is the all-time high of MRNA?

How much has MRNA gained this year?

How volatile is MRNA?

MRNA month-end closes

What was the biggest price drop for MRNA?

Which month has historically been best for MRNA?